EGFR and neoplasm: Somatic mutations in cancer driver genes, tumor suppressors, and amplified oncogenes such as EGFR, RAS, BRAF, MYC, isocitrate dehydrogenase (IDH), and fumarate hydratase (FH) have been shown to be linked to specific alterations in metabolic activity in cancer cells (11, –, 14).